| Year |
Citation |
Score |
| 2021 |
Bode BW, Carlson A, Liu R, Hardy T, Bergenstal RM, Boyd J, Morrett S, Ignaut DA. Ultra Rapid Lispro Demonstrates Similar Time in Target Range to Lispro With a Hybrid Closed-Loop System. Diabetes Technology & Therapeutics. PMID 34270335 DOI: 10.1089/dia.2021.0184 |
0.314 |
|
| 2021 |
Brown SA, Forlenza GP, Bode BW, Pinsker JE, Levy CJ, Criego AB, Hansen DW, Hirsch IB, Carlson AL, Bergenstal RM, Sherr JL, Mehta SN, Laffel LM, Shah VN, Bhargava A, et al. Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes. Diabetes Care. PMID 34099518 DOI: 10.2337/dc21-0172 |
0.334 |
|
| 2021 |
Warren M, Bode B, Cho JI, Liu R, Tobian J, Hardy T, Chigutsa F, Phillip M, Horowitz B, Ignaut D. Improved Postprandial Glucose Control With Ultra Rapid Lispro Versus Lispro With Continuous Subcutaneous Insulin Infusion in Type 1 Diabetes: PRONTO-Pump-2. Diabetes, Obesity & Metabolism. PMID 33687783 DOI: 10.1111/dom.14368 |
0.393 |
|
| 2021 |
Mehta SN, Tinsley LJ, Kruger D, Bode B, Layne JE, Huyett LM, Dryga K, Dumais B, Ly TT, Laffel LM. Improved Glycemic Control Following Transition to Tubeless Insulin Pump Therapy in Adults With Type 1 Diabetes. Clinical Diabetes : a Publication of the American Diabetes Association. 39: 72-79. PMID 33551556 DOI: 10.2337/cd20-0022 |
0.364 |
|
| 2021 |
SHAH V, CRIEGO AB, CARLSON AL, BHARGAVA A, BODE BW, BROWN SA, FORLENZA GP, LEVY CJ, MEHTA SN, LAFFEL LM, ALEPPO G, BUCKINGHAM BA, DESALVO D, HIRSCH IB, MACLEISH SA, et al. 716-P: Transition from Multiple Daily Injections (MDI) to Omnipod 5 Automated Insulin Delivery System Improves A1C in Type 1 Diabetes (T1D) Diabetes. 70: 716-P. DOI: 10.2337/DB21-716-P |
0.325 |
|
| 2021 |
Bode BW, Peters A, Carlson AL, Dumais B, Lowen S, Vienneau T, Huyett L, Ly TT. The Use of Omnipod® 5 Automated Insulin Delivery System in Adults With Type 2 Diabetes With Suboptimal Glycemic Management: From Injections to Closed-Loop Therapy Journal of the Endocrine Society. 5: A479-A479. DOI: 10.1210/jendso/bvab048.980 |
0.349 |
|
| 2020 |
Forlenza GP, Buckingham BA, Brown S, Bode BW, Levy C, Criego A, Wadwa RP, Cobry E, Slover RJ, Messer L, Berget C, McCoy S, Ekhlaspour L, Kingman RS, Voelmle MK, et al. First outpatient evaluation of a tubeless automated insulin delivery system with customizable glucose targets in children and adults with type 1 diabetes. Diabetes Technology & Therapeutics. PMID 33325779 DOI: 10.1089/dia.2020.0546 |
0.329 |
|
| 2020 |
Bode BW, Cengiz E, Wadwa RP, Banks P, Danne T, Kushner JA, McGuire DK, Peters A, Strumph P, Sawhney S. Effects of Sotagliflozin Combined with Intensive Insulin Therapy in Young Adults with Poorly Controlled Type 1 Diabetes: The JDRF Sotagliflozin Study. Diabetes Technology & Therapeutics. PMID 32640846 DOI: 10.1089/dia.2020.0079 |
0.311 |
|
| 2020 |
Bode BW, Garg SK, Norwood P, Morales C, Hardy T, Liu R, Ignaut DA. Compatibility and Safety of Ultra Rapid Lispro with Continuous Subcutaneous Insulin Infusion in Patients With Type 1 Diabetes: PRONTO-Pump Study. Diabetes Technology & Therapeutics. PMID 32640842 DOI: 10.1089/dia.2020.0224 |
0.337 |
|
| 2020 |
Pratley RE, Kanapka LG, Rickels MR, Ahmann A, Aleppo G, Beck R, Bhargava A, Bode BW, Carlson A, Chaytor NS, Fox DS, Goland R, Hirsch IB, Kruger D, Kudva YC, et al. Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes: A Randomized Clinical Trial. Jama. 323: 2397-2406. PMID 32543682 DOI: 10.1001/Jama.2020.6928 |
0.309 |
|
| 2020 |
Malecki MT, Cao D, Liu R, Hardy T, Bode BW, Bergenstal RM, Bue-Valleskey J. Ultra Rapid Lispro Improves Postprandial Glucose Control and Time in Range in Type 1 Diabetes Compared to Lispro: PRONTO-T1D Continuous Glucose Monitoring Sub-Study. Diabetes Technology & Therapeutics. PMID 32453647 DOI: 10.1089/dia.2020.0129 |
0.31 |
|
| 2020 |
BODE BW, BOYD J, SHAH A, PARKES D, GHOSH S, CHERRINGTON AD. 7-LB: Insulin and Glucagon Coadministration in Type 1 Diabetes Prevents Hypoglycemia without Worsening Hyperglycemia Diabetes. 69: 7-LB. DOI: 10.2337/db20-7-lb |
0.366 |
|
| 2020 |
BODE BW, CLARKE JG. 116-LB: Evaluating the Impact of Glucommander on Improvement in Time-in-Range (TIR) in Type 2 Diabetes Using Continuous Glucose Monitoring Diabetes. 69: 116-LB. DOI: 10.2337/db20-116-lb |
0.324 |
|
| 2019 |
Klonoff D, Bode B, Cohen N, Penn M, Geho WB, Muchmore DB. Divergent Hypoglycemic Effects of Hepatic-Directed Prandial Insulin: A Six-Month Phase 2b Study in Type 1 Diabetes. Diabetes Care. PMID 31551249 DOI: 10.2337/dc19-0152 |
0.334 |
|
| 2019 |
Bode BW, Iotova V, Kovarenko M, Laffel LM, Rao PV, Deenadayalan S, Ekelund M, Larsen SF, Danne T. Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial. Diabetes Care. PMID 31076415 DOI: 10.2337/dc19-0009 |
0.347 |
|
| 2019 |
Pettus J, Gill J, Paranjape S, Stewart J, Malla S, Edelman S, Bergenstal RM, Bode B. Efficacy and safety of a morning injection of insulin glargine 300 units/mL versus insulin glargine 100 units/mL in adult patients with type 1 diabetes: A multicentre, randomized controlled trial using continuous glucose monitoring. Diabetes, Obesity & Metabolism. PMID 30993855 DOI: 10.1111/dom.13751 |
0.365 |
|
| 2019 |
Danne T, Garg S, Peters AL, Buse JB, Mathieu C, Pettus JH, Alexander CM, Battelino T, Ampudia-Blasco FJ, Bode BW, Cariou B, Close KL, Dandona P, Dutta S, Ferrannini E, et al. International Consensus on Risk Management of Diabetic Ketoacidosis in Patients with Type 1 Diabetes Treated with Sodium-Glucose Cotransporter (SGLT) Inhibitors. Diabetes Care. PMID 30728224 DOI: 10.2337/Dc18-2316 |
0.327 |
|
| 2019 |
Heise T, Meiffren G, Alluis B, Seroussi C, Ranson A, Arrubla J, Correia J, Gaudier M, Soula O, Soula R, DeVries JH, Klein O, Bode B. BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study. Diabetes, Obesity & Metabolism. 21: 1066-1070. PMID 30565407 DOI: 10.1111/dom.13621 |
0.324 |
|
| 2019 |
MEHTA SN, KRUGER DF, BODE BW, LAYNE JE, DUMAIS B, GALLAGHER JR, LY TT. 1061-P: Effect of the Omnipod® Insulin Management System on Glycemic Control in Adults with Type 1 Diabetes Previously Treated with MDI or CSII Diabetes. 68: 1061-P. DOI: 10.2337/DB19-1061-P |
0.339 |
|
| 2018 |
Bowering K, Rodbard HW, Russell-Jones D, Bode B, Harris S, Piletic M, Heller S, Woo V, Babu V, Dethlefsen C, Mathieu C. Investigating the Association Between Baseline Characteristics (HbA1c and Body Mass Index) and Clinical Outcomes of Fast-Acting Insulin Aspart in People with Diabetes: A Post Hoc Analysis. Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders. PMID 30547388 DOI: 10.1007/s13300-018-0553-7 |
0.326 |
|
| 2018 |
Bowering K, Harvey J, Kolaczynski JW, Snyder JW, Bode BW. Mealtime fast-acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin-resistant Type 2 diabetes. Diabetic Medicine : a Journal of the British Diabetic Association. PMID 30466191 DOI: 10.1111/dme.13866 |
0.353 |
|
| 2018 |
Wood MA, Shulman DI, Forlenza GP, Bode BW, Pinhas-Hamiel O, Buckingham BA, Kaiserman KB, Liljenquist DR, Bailey TS, Shin J, Huang S, Chen X, Cordero TL, Lee SW, Kaufman FR. In-Clinic Evaluation of the MiniMed 670G System "Suspend Before Low" Feature in Children with Type 1 Diabetes. Diabetes Technology & Therapeutics. PMID 30299976 DOI: 10.1089/dia.2018.0209 |
0.303 |
|
| 2018 |
Akturk HK, Snell-Bergeon JK, Rewers A, Klaff LJ, Bode BW, Peters AL, Bailey TS, Garg SK. Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study. Diabetes Technology & Therapeutics. PMID 30207748 DOI: 10.1089/Dia.2018.0200 |
0.362 |
|
| 2018 |
Buse JB, Garg SK, Rosenstock J, Bailey TS, Banks P, Bode BW, Danne T, Kushner JA, Lane WS, Lapuerta P, McGuire DK, Peters AL, Reed J, Sawhney S, Strumph P. Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study. Diabetes Care. PMID 29937430 DOI: 10.2337/dc18-0343 |
0.358 |
|
| 2018 |
Christiansen MP, Klaff LJ, Brazg R, Chang AR, Levy CJ, Lam D, Denham DS, Atiee G, Bode BW, Walters SJ, Kelley L, Bailey TS. A Prospective Multicenter Evaluation of the Accuracy of a Novel Implanted Continuous Glucose Sensor: PRECISE II. Diabetes Technology & Therapeutics. PMID 29381090 DOI: 10.1089/dia.2017.0142 |
0.32 |
|
| 2018 |
Mathieu C, Bode BW, Franek E, Philis-Tsimikas A, Rose L, Graungaard T, Birk Østerskov A, Russell-Jones D. Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): a 52-week, randomized, treat-to-target, phase 3 trial. Diabetes, Obesity & Metabolism. PMID 29316130 DOI: 10.1111/dom.13205 |
0.361 |
|
| 2018 |
BUSE JB, GARG SK, ROSENSTOCK J, BAILEY TS, BANKS PL, BODE BW, DANNE T, KUSHNER JA, LANE W, LAPUERTA P, MCGUIRE DK, PETERS AL, REED JH, SAWHNEY S, STRUMPH P. Fifty-Two-Week Efficacy and Safety of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes (inTandem1) Diabetes. 67: 212-OR. DOI: 10.2337/DB18-212-OR |
0.318 |
|
| 2018 |
Rabasa-Lhoret R, Philis-Tsimikas A, Bode BW, Franek E, Rose L, Buchholtz K, Demissie M, Pieber TR. Improved Glycemic Control with Carbohydrate Counting for Adjustment of Fast-Acting Insulin Aspart vs. Insulin Aspart in Subjects with Type 1 Diabetes Canadian Journal of Diabetes. 42. DOI: 10.1016/J.Jcjd.2018.08.023 |
0.361 |
|
| 2017 |
Zijlstra E, Demissie M, Graungaard T, Heise T, Nosek L, Bode B. Investigation of Pump Compatibility of Fast-Acting Insulin Aspart in Subjects With Type 1 Diabetes. Journal of Diabetes Science and Technology. 12: 145-151. PMID 28918652 DOI: 10.1177/1932296817730375 |
0.342 |
|
| 2017 |
Beck RW, Riddlesworth TD, Ruedy KJ, Kollman C, Ahmann AJ, Bergenstal RM, Bhargava A, Bode BW, Haller S, Kruger DF, McGill JB, Polonsky W, Price D, Toschi E. Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial. The Lancet. Diabetes & Endocrinology. PMID 28711468 DOI: 10.1016/S2213-8587(17)30217-6 |
0.395 |
|
| 2017 |
Bowering K, Case C, Harvey J, Reeves M, Sampson M, Strzinek R, Bretler DM, Bang RB, Bode BW. Faster Aspart Versus Insulin Aspart As Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial. Diabetes Care. PMID 28483786 DOI: 10.2337/dc16-1770 |
0.355 |
|
| 2017 |
Russell-Jones D, Bode BW, De Block C, Franek E, Heller SR, Mathieu C, Philis-Tsimikas A, Rose L, Woo VC, Østerskov AB, Graungaard T, Bergenstal RM. Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (Onset 1). Diabetes Care. PMID 28356319 DOI: 10.2337/dc16-1771 |
0.357 |
|
| 2017 |
Aleppo G, Ruedy KJ, Riddlesworth TD, Kruger DF, Peters AL, Hirsch I, Bergenstal RM, Toschi E, Ahmann AJ, Shah VN, Rickels MR, Bode BW, Philis-Tsimikas A, Pop-Busui R, Rodriguez H, et al. REPLACE-BG: A Randomized Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Well-Controlled Adults With Type 1 Diabetes. Diabetes Care. PMID 28209654 DOI: 10.2337/Dc16-2482 |
0.316 |
|
| 2017 |
Bode BW, Kaufman FR, Vint N. An Expert Opinion on Advanced Insulin Pump Use in Youth with Type 1 Diabetes. Diabetes Technology & Therapeutics. PMID 28135116 DOI: 10.1089/dia.2016.0354 |
0.328 |
|
| 2017 |
Garg SK, Weinzimer SA, Tamborlane WV, Buckingham BA, Bode BW, Bailey TS, Brazg RL, Ilany J, Slover RH, Anderson SM, Bergenstal RM, Grosman B, Roy A, Cordero TL, Shin J, et al. Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes. Diabetes Technology & Therapeutics. PMID 28134564 DOI: 10.1089/dia.2016.0421 |
0.337 |
|
| 2017 |
Bode BW, Johnson JA, Hyveled L, Tamer SC, Demissie M. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion. Diabetes Technology & Therapeutics. PMID 28055230 DOI: 10.1089/dia.2016.0350 |
0.379 |
|
| 2017 |
Milosevski V, Bowering K, Bode B, Harris S, Piletic M, Babu V, Dethlefsen C, Rodbard HW. The Impact of Baseline BMI and HbA1c on Glycemic Control After Treatment with Fast-Acting Insulin Aspart in Individuals with Type 2 Diabetes Canadian Journal of Diabetes. 41: S55. DOI: 10.1016/J.JCJD.2017.08.148 |
0.347 |
|
| 2016 |
Linjawi S, Bode BW, Chaykin LB, Courrèges JP, Handelsman Y, Lehmann LM, Mishra A, Simpson RW. The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial. Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders. PMID 27943107 DOI: 10.1007/s13300-016-0218-3 |
0.334 |
|
| 2016 |
Bergenstal RM, Garg S, Weinzimer SA, Buckingham BA, Bode BW, Tamborlane WV, Kaufman FR. Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes. Jama. PMID 27629148 DOI: 10.1001/jama.2016.11708 |
0.351 |
|
| 2016 |
Frid AH, Kreugel G, Grassi G, Halimi S, Hicks D, Hirsch LJ, Smith MJ, Wellhoener R, Bode BW, Hirsch IB, Kalra S, Ji L, Strauss KW. New Insulin Delivery Recommendations. Mayo Clinic Proceedings. 91: 1231-55. PMID 27594187 DOI: 10.1016/j.mayocp.2016.06.010 |
0.325 |
|
| 2016 |
Rodbard HW, Bode BW, Harris SB, Rose L, Lehmann L, Jarlov H, Thurman J. Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial. Diabetic Medicine : a Journal of the British Diabetic Association. PMID 27589252 DOI: 10.1111/dme.13256 |
0.344 |
|
| 2016 |
Aloi J, Bode BW, Ullal J, Chidester P, McFarland RS, Bedingfield AE, Mabrey M, Booth R, Mumpower A, Wallia A. Comparison of an Electronic Glycemic Management System Versus Provider-Managed Subcutaneous Basal Bolus Insulin Therapy in the Hospital Setting. Journal of Diabetes Science and Technology. PMID 27555601 DOI: 10.1177/1932296816664746 |
0.312 |
|
| 2016 |
Mathieu C, Zinman B, Hemmingsson JU, Woo V, Colman P, Christiansen E, Linder M, Bode B. Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial. Diabetes Care. PMID 27506222 DOI: 10.2337/dc16-0691 |
0.346 |
|
| 2016 |
Kumar S, Jang HC, Guvener ND, Skjøth TV, Endahl L, Bode B. Efficacy and safety of once-daily insulin degludec/insulin aspart compared with once-daily insulin glargine in participants with Type 2 diabetes: a randomized, treat-to-target study. Diabetic Medicine : a Journal of the British Diabetic Association. PMID 27027878 DOI: 10.1111/dme.13125 |
0.349 |
|
| 2016 |
Cengiz E, Bode B, Van Name M, Tamborlane WV. Moving toward the ideal insulin for insulin pumps Expert Review of Medical Devices. 13: 57-69. DOI: 10.1586/17434440.2016.1109442 |
0.336 |
|
| 2016 |
Bowering K, Case C, Harvey J, Reeves M, Sampson M, Strzinek R, Bretler D, Bang RB, Pakseresht A, Bode BW. Faster-Acting Insulin Aspart vs. Insulin Aspart in Basal-Bolus Therapy Improved Postprandial Glycemic Control in Uncontrolled T2D in the Onset® 2 Trial Canadian Journal of Diabetes. 40: S57. DOI: 10.1016/J.JCJD.2016.08.160 |
0.301 |
|
| 2015 |
Bode BW, McGill JB, Lorber DL, Gross JL, Chang PC, Bregman DB. Inhaled Technosphere Insulin Compared With Injected Prandial Insulin in Type 1 Diabetes: A Randomized 24-Week Trial. Diabetes Care. PMID 26180109 DOI: 10.2337/Dc15-0075 |
0.33 |
|
| 2015 |
Sands AT, Zambrowicz BP, Rosenstock J, Lapuerta P, Bode BW, Garg SK, Buse JB, Banks P, Heptulla R, Rendell M, Cefalu WT, Strumph P. Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes. Diabetes Care. 38: 1181-8. PMID 26049551 DOI: 10.2337/Dc14-2806 |
0.335 |
|
| 2015 |
Weiss R, Garg SK, Bergenstal RM, Klonoff DC, Bode BW, Bailey TS, Thrasher J, Schwartz F, Welsh JB, Kaufman FR. Predictors of Hypoglycemia in the ASPIRE In-Home Study and Effects of Automatic Suspension of Insulin Delivery. Journal of Diabetes Science and Technology. PMID 25986629 DOI: 10.1177/1932296815586014 |
0.338 |
|
| 2015 |
Gough SCL, Bode BW, Woo VC, Rodbard HW, Linjawi S, Zacho M, Reiter PD, Buse JB. One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: Results of a 26-week extension to a 26-week main trial Diabetes, Obesity and Metabolism. DOI: 10.1111/dom.12498 |
0.333 |
|
| 2014 |
Gough SC, Bode B, Woo V, Rodbard HW, Linjawi S, Poulsen P, Damgaard LH, Buse JB. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. The Lancet. Diabetes & Endocrinology. 2: 885-93. PMID 25190523 DOI: 10.1016/S2213-8587(14)70174-3 |
0.34 |
|
| 2014 |
Bode BW, Chaykin LB, Sussman AM, Warren ML, Niemeyer M, Rabøl R, Rodbard HW. Efficacy and Safety of Insulin Degludec 200 U/mL and Insulin Degludec 100 U/mL in Patients with Type 2 Diabetes (Begin: Compare). Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 20: 785-91. PMID 24518180 DOI: 10.4158/EP13411.OR |
0.347 |
|
| 2013 |
Zinman B, DeVries JH, Bode B, Russell-Jones D, Leiter LA, Moses A, Johansen T, Ratner R. Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials. The Lancet. Diabetes & Endocrinology. 1: 123-31. PMID 24622318 DOI: 10.1016/S2213-8587(13)70013-5 |
0.346 |
|
| 2013 |
Klonoff DC, Bergenstal RM, Garg SK, Bode BW, Meredith M, Slover RH, Ahmann A, Welsh JB, Lee SW. ASPIRE In-Home: rationale, design, and methods of a study to evaluate the safety and efficacy of automatic insulin suspension for nocturnal hypoglycemia. Journal of Diabetes Science and Technology. 7: 1005-10. PMID 23911183 DOI: 10.1177/193229681300700424 |
0.303 |
|
| 2013 |
Bode BW, Buse JB, Fisher M, Garg SK, Marre M, Merker L, Renard E, Russell-Jones DL, Hansen CT, Rana A, Heller SR. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trial. Diabetic Medicine : a Journal of the British Diabetic Association. 30: 1293-7. PMID 23710902 DOI: 10.1111/dme.12243 |
0.349 |
|
| 2013 |
Bode B, Stenlöf K, Sullivan D, Fung A, Usiskin K. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hospital Practice (1995). 41: 72-84. PMID 23680739 DOI: 10.3810/hp.2013.04.1020 |
0.304 |
|
| 2013 |
Heller S, Bode B, Kozlovski P, Svendsen AL. Meta-analysis of insulin aspart versus regular human insulin used in a basal-bolus regimen for the treatment of diabetes mellitus. Journal of Diabetes. 5: 482-91. PMID 23586846 DOI: 10.1111/1753-0407.12060 |
0.32 |
|
| 2013 |
Garg SK, Moser EG, Bode BW, Klaff LJ, Hiatt WR, Beatson C, Snell-Bergeon JK. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 19: 19-28. PMID 23186950 DOI: 10.4158/Ep12100.Or |
0.333 |
|
| 2013 |
Buse JB, Gough SC, Woo VC, Rodbard HW, Linjawi S, Poulsen P, Da mgaard LH, Bode BW. 1.1 IDegLira, a Novel Fixed Ratio Combination of Insulin Degludec and Liraglutide, is Efficacious and Safe in Subjects with Type 2 Diabetes: A Large, Randomized Phase 3 Trial (65-OR) Nederlands Tijdschrift Voor Diabetologie. 11: 74-75. DOI: 10.1007/s12467-013-0026-6 |
0.32 |
|
| 2012 |
Ratner RE, Gough SC, Mathieu C, Del Prato S, Bode B, Mersebach H, Endahl L, Zinman B. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes, Obesity & Metabolism. 15: 175-84. PMID 23130654 DOI: 10.1111/dom.12032 |
0.36 |
|
| 2012 |
Bergenstal RM, Bode BW, Tamler R, Trence DL, Stenger P, Schachner HC, Fullam J, Pardo S, Kohut T, Fisher WA. Advanced meter features improve postprandial and paired self-monitoring of blood glucose in individuals with diabetes: results of the Actions with the CONTOUR Blood Glucose Meter and Behaviors in Frequent Testers (ACT) study. Diabetes Technology & Therapeutics. 14: 851-7. PMID 23013200 DOI: 10.1089/dia.2012.0051 |
0.301 |
|
| 2012 |
Hirsch IB, Bode B, Courreges JP, Dykiel P, Franek E, Hermansen K, King A, Mersebach H, Davies M. Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial. Diabetes Care. 35: 2174-81. PMID 22933438 DOI: 10.2337/dc11-2503 |
0.329 |
|
| 2012 |
Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L, Renard E, Russell-Jones D, Philotheou A, Francisco AM, Pei H, Bode B. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 379: 1489-97. PMID 22521071 DOI: 10.1016/S0140-6736(12)60204-9 |
0.36 |
|
| 2012 |
Asche CV, Bode B, Busk AK, Nair SR. The economic and clinical benefits of adequate insulin initiation and intensification in people with type 2 diabetes mellitus Diabetes, Obesity and Metabolism. 14: 47-57. PMID 21834876 DOI: 10.1111/j.1463-1326.2011.01487.x |
0.358 |
|
| 2012 |
Bode BW, Heller S, Hansen CT, Rana A, Russell-Jones DL. Insulin Degludec Improves Glycemic Control with Lower Nocturnal Hypoglycemia Risk than Insulin Glargine: A 2-year Randomized Trial in Type 1 Diabetes Canadian Journal of Diabetes. 36: S57-S58. DOI: 10.1016/j.jcjd.2012.07.401 |
0.354 |
|
| 2011 |
Frias JP, Bode BW, Bailey TS, Kipnes MS, Brunelle R, Edelman SV. A 16-week open-label, multicenter pilot study assessing insulin pump therapy in patients with type 2 diabetes suboptimally controlled with multiple daily injections. Journal of Diabetes Science and Technology. 5: 887-93. PMID 21880230 DOI: 10.1177/193229681100500410 |
0.34 |
|
| 2011 |
van Bon AC, Bode BW, Sert-Langeron C, DeVries JH, Charpentier G. Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial. Diabetes Technology & Therapeutics. 13: 607-14. PMID 21457066 DOI: 10.1089/dia.2010.0224 |
0.344 |
|
| 2011 |
Battelino T, Bode BW. Continuous glucose monitoring in 2010 International Journal of Clinical Practice. Supplement. 10-15. PMID 21323807 DOI: 10.1111/j.1742-1241.2010.02573.x |
0.343 |
|
| 2011 |
Wilson DM, Xing D, Beck RW, Block J, Bode B, Fox LA, Hirsch I, Kollman C, Laffel L, Ruedy KJ, Steffes M, Tamborlane WV. Hemoglobin A1c and mean glucose in patients with type 1 diabetes: analysis of data from the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized trial. Diabetes Care. 34: 540-4. PMID 21266647 DOI: 10.2337/dc10-1054 |
0.327 |
|
| 2011 |
Asche C, Bode B, Busk A, Nair S. PDB14 Assessment of the Clinical and Economic Benefits of Adequate Insulin Initiation and Intensification in People with Type 2 Diabetes Mellitus Value in Health. 14: A474. DOI: 10.1016/J.JVAL.2011.08.1317 |
0.341 |
|
| 2010 |
Kruger DF, Bode B, Spollett GR. Understanding glp-1 analogs and enhancing patient success Diabetes Educator. 36: 44-72. PMID 20736387 DOI: 10.1177/0145721710374370 |
0.327 |
|
| 2010 |
Edelman SV, Bode BW, Bailey TS, Kipnes MS, Brunelle R, Chen X, Frias JP. Insulin pump therapy in patients with type 2 diabetes safely improved glycemic control using a simple insulin dosing regimen. Diabetes Technology & Therapeutics. 12: 627-33. PMID 20615104 DOI: 10.1089/dia.2010.0034 |
0.348 |
|
| 2010 |
Bode BW. Insulin pump use in type 2 diabetes Diabetes Technology and Therapeutics. 12. PMID 20515301 DOI: 10.1089/dia.2009.0192 |
0.367 |
|
| 2010 |
Nardacci EA, Bode BW, Hirsch IB. Individualizing care for the many: The evolving role of professional continuous glucose monitoring systems in clinical practice Diabetes Educator. 36. PMID 20407139 DOI: 10.1177/0145721710362798 |
0.359 |
|
| 2009 |
Heller S, Koenen C, Bode B. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial. Clinical Therapeutics. 31: 2086-97. PMID 19922879 DOI: 10.1016/j.clinthera.2009.10.006 |
0.346 |
|
| 2009 |
Bode BW. Defining the importance of daily glycemic control and implications for type 2 diabetes management Postgraduate Medicine. 121: 82-93. PMID 19820277 DOI: 10.3810/pgm.2009.09.2055 |
0.341 |
|
| 2009 |
Bode B, Beck RW, Xing D, Gilliam L, Hirsch I, Kollman C, Laffel L, Ruedy KJ, Tamborlane WV, Weinzimer S, Wolpert H. Sustained benefit of continuous glucose monitoring on A1C, glucose profiles, and hypoglycemia in adults with type 1 diabetes. Diabetes Care. 32: 2047-9. PMID 19675193 DOI: 10.2337/dc09-0846 |
0.322 |
|
| 2009 |
Beck RW, Hirsch IB, Laffel L, Tamborlane WV, Bode BW, Buckingham B, Chase P, Clemons R, Fiallo-Scharer R, Fox LA, Gilliam LK, Huang ES, Kollman C, Kowalski AJ, et al. The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care. 32: 1378-83. PMID 19429875 DOI: 10.2337/dc09-0108 |
0.336 |
|
| 2009 |
Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet (London, England). 373: 473-81. PMID 18819705 DOI: 10.1016/S0140-6736(08)61246-5 |
0.331 |
|
| 2008 |
Hirsch IB, Bode BW, Childs BP, Close KL, Fisher WA, Gavin JR, Ginsberg BH, Raine CH, Verderese CA. Self-Monitoring of Blood Glucose (SMBG) in insulin- and non-insulin-using adults with diabetes: consensus recommendations for improving SMBG accuracy, utilization, and research. Diabetes Technology & Therapeutics. 10: 419-39. PMID 18937550 DOI: 10.1089/dia.2008.0104 |
0.362 |
|
| 2008 |
Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, Fiallo-Scharer R, Fox LA, Gilliam LK, Hirsch IB, Huang ES, Kollman C, Kowalski AJ, Laffel L, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. The New England Journal of Medicine. 359: 1464-76. PMID 18779236 DOI: 10.1056/NEJMoa0805017 |
0.333 |
|
| 2008 |
Bode B, Silver M, Weiss R, Martin K. Evaluation of a continuous glucose monitoring system for home-use conditions Managed Care (Langhorne, Pa.). 17: 40-45. PMID 18777789 |
0.341 |
|
| 2008 |
Bode BW. Incorporating postprandial and fasting plasma glucose into clinical management strategies Insulin. 3: 17-27. DOI: 10.1016/S1557-0843(08)80006-1 |
0.35 |
|
| 2007 |
Bode BW. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: Insulin pump therapy versus multiple daily injections Clinical Therapeutics. 29. PMID 18191065 DOI: 10.1016/j.clinthera.2007.12.013 |
0.362 |
|
| 2007 |
Raskin PR, Hollander PA, Lewin A, Gabbay RA, Bode B, Garber AJ. Basal insulin or premix analogue therapy in type 2 diabetes patients European Journal of Internal Medicine. 18: 56-62. DOI: 10.1016/j.ejim.2006.09.006 |
0.344 |
|
| 2005 |
Bode BW, Steed RD, Schleusener DS, Strange P. Switch to multiple daily injections with insulin glargine and insulin lispro from continuous subcutaneous insulin infusion with insulin lispro: a randomized, open-label study using a continuous glucose monitoring system. Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 11: 157-64. PMID 16239201 DOI: 10.4158/EP.11.3.157 |
0.325 |
|
| 2005 |
DeFronzo RA, Bergenstal RM, Cefalu WT, Pullman J, Lerman S, Bode BW, Phillips LS. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. Diabetes Care. 28: 1922-8. PMID 16043733 DOI: 10.2337/DIACARE.28.8.1922 |
0.311 |
|
| 2005 |
Hirsch IB, Bode BW, Garg S, Lane WS, Sussman A, Hu P, Santiago OM, Kolaczynski JW. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care. 28: 533-8. PMID 15735183 |
0.339 |
|
| 2005 |
Tanenberg R, Bode B, Lane W, Levetan C, Mestman J, Harmel AP, Tobian J, Gross T, Mastrototaro J. Use of the Continuous Glucose Monitoring System to guide therapy in patients with insulin-treated diabetes: a randomized controlled trial. Mayo Clinic Proceedings. 79: 1521-6. PMID 15595336 DOI: 10.4065/79.12.1521 |
0.368 |
|
| 2004 |
Ergun-Longmire B, Marker J, Zeidler A, Rapaport R, Raskin P, Bode B, Schatz D, Vargas A, Rogers D, Schwartz S, Malone J, Krischer J, Maclaren NK. Oral insulin therapy to prevent progression of immune-mediated (type 1) diabetes. Annals of the New York Academy of Sciences. 1029: 260-77. PMID 15681764 DOI: 10.1196/annals.1309.057 |
0.318 |
|
| 2003 |
Raskin P, Bode BW, Marks JB, Hirsch IB, Weinstein RL, McGill JB, Peterson GE, Mudaliar SR, Reinhardt RR. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care. 26: 2598-603. PMID 12941725 DOI: 10.2337/diacare.26.9.2598 |
0.339 |
|
| 2003 |
Bode BW, Tamborlane WV, Davidson PC. Insulin pump therapy in the 21st century Sendrom. 15: 44-51. |
0.321 |
|
| 2002 |
Bode BW. Intensive insulin therapy and insulin pumps Postgraduate Medicine. 112: 17-21. PMID 19667601 DOI: 10.3810/pgm.11.2002.suppl21.113 |
0.309 |
|
| 2002 |
Bode BW, Sabbah HT, Gross TM, Fredrickson LP, Davidson PC. Diabetes management in the new millennium using insulin pump therapy. Diabetes/Metabolism Research and Reviews. 18: S14-20. PMID 11921425 DOI: 10.1002/dmrr.205 |
0.335 |
|
| 2002 |
Bode B, Weinstein R, Bell D, McGill J, Nadeau D, Raskin P, Davidson J, Henry R, Huang WC, Reinhardt RR. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes. Diabetes Care. 25: 439-44. PMID 11874927 DOI: 10.2337/DIACARE.25.3.439 |
0.335 |
|
| 2001 |
Bode BW, Sabbah H, Davidson PC. What's ahead in glucose monitoring? New techniques hold promise for improved ease and accuracy Postgraduate Medicine. 109. PMID 11317468 DOI: 10.3810/pgm.2001.04.906 |
0.324 |
|
| 2001 |
Bode BW, Strange P. Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes Diabetes Care. 24: 69-72. PMID 11194244 DOI: 10.2337/DIACARE.24.1.69 |
0.322 |
|
| 2000 |
Bode BW, Hirsch IB. Using the continuous glucose monitoring system to improve the management of type 1 diabetes Diabetes Technology and Therapeutics. 2. PMID 11469631 DOI: 10.1089/15209150050214113 |
0.329 |
|
| 2000 |
Gross TM, Bode BW, Einhorn D, Kayne DM, Reed JH, White NH, Mastrototaro JJ. Performance evaluation of the MiniMed continuous glucose monitoring system during patient home use. Diabetes Technology & Therapeutics. 2: 49-56. PMID 11467320 DOI: 10.1089/152091500316737 |
0.314 |
|
| 2000 |
Bode BW, Gross TM, Thornton KR, Mastrototaro JJ. Erratum to “Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study” Diabetes Research and Clinical Practice. 47: 225. DOI: 10.1016/S0168-8227(00)00124-8 |
0.317 |
|
| 1999 |
Bode BW, Gross TM, Thornton KR, Mastrototaro JJ. Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study. Diabetes Research and Clinical Practice. 46: 183-90. PMID 10624783 DOI: 10.1016/S0168-8227(99)00113-8 |
0.319 |
|
| Show low-probability matches. |